ReviewDrug delivery2026
Harnessing fluorescent probes for molecular diagnosis and theranostics of atherosclerosis.
Review in Drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Affinity Peptide-Based Circularly Permuted Fluorescent Protein Biosensors Loaded in a Microfluidic System for Systemic Lupus Erythematosus Diagnosis.Sensors (Basel, Switzerland) · 2026Article
- Development and epidemiological investigation of a TaqMan-based multiplex real-time quantitative PCR assay for simultaneous detection of five bovine viruses (BVDV, AKAV, BNoV, BEV, and BCoV).Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease remains a leading cause of morbidity and mortality worldwide, posing a serious threat to human health. Atherosclerosis (AS), the pathological basis of most cardiovascular diseases, is characterized by arterial wall thickening caused by chronic inflammation. In recent years, molecular probes have attracted much attention as versatile tools for the diagnosis and treatment of AS, offering capabilities in imaging, drug monitoring, and surgical navigation. The existing probes include fluorescent probes, SERS probes, nuclear medicine probes, self-assembled nanoprobes, UC-FRET probes, photothermal probes, and multimodal probes. Among them, fluorescent probes have emerged as a research focus because of their excellent targeting effect, biocompatibility, and multimodal compatibility. This review summarizes recent advances in the classification and synthesis of fluorescent probes, their targeted applications in AS, and their auxiliary diagnosis and treatment of AS. By highlighting current progress and key challenges, this work aims to provide valuable insights to support further development and facilitate the advancement of fluorescent probe technologies in the context of AS, while promoting the clinical application of fluorescent probes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.